Remove 2028 Remove Pharmaceuticals Remove Trials
article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Drive: Drug Pricing

Permission granted by Incyte Dive Brief: Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. You can unsubscribe at anytime. Last year, Jakafi brought in nearly $2.8 billion in sales.

Therapies 117
article thumbnail

The Competitive Edge of Biosimilars

DrugBank

Due to the less extensive clinical trial requirements and the competitive nature of the biosimilar market, these biologics can be produced and marketed at significantly lower prices than their reference counterparts. billion by 2028. The primary advantage is cost-effectiveness.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2021 Biotech IPOs Get Off to a Roaring Start

The Pharma Data

TC-210 is currently in a Phase I/II trial for mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. TC-110 is in a Phase I/II trial for CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL).

article thumbnail

Article EMA Thank You Proposal for IVDR extension also impacts MDR, EUDAMED

Agency IQ

For example, the European pharmaceutical trade association EFPIA expressed concern over the delays the IVDR had been causing in drug clinical application approvals. These requirements are similar to what is already required for critical pharmaceutical products. Once the E.U.

article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

The proposal will be discussed at the Council of the EU Working Party on Pharmaceuticals and Medical Devices, taking place January 30. Companion diagnostics (CDx) and cancer trials: In 2023, the MDCG published guidance documents on classifying CDx. This is an extremely recent development, and an emerging area.

FDA 40
article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.  Pharmaceutical Market Analysis The global pharmaceutical market revenue in 2024 is projected to be 1.15

article thumbnail

Bayer, Broad Institute Extend Cardiovascular Drug Research Pact

The Pharma Data

The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.